Meta-analysis of the efficacy of different therapy regimens in eradicating Helicobacter pylori Metaanalyse zur feststellung der keimeradizierenden potenz verschiedener therapieschemata bei Helicobacter-pylori-infektion
Wiener Medizinische Wochenschrift, cilt.148, sa.20, ss.464-468, 1998 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 148 Sayı: 20
- Basım Tarihi: 1998
- Dergi Adı: Wiener Medizinische Wochenschrift
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.464-468
- Anahtar Kelimeler: Cost analysis, Eradication rates, Helicobacter pylori therapy, Meta-analysis, Therapy side effects
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır
Özet
Helicobacter pylori is the most common bacterial pathogen world-wide and has been identified in all countries. As long-term infection with H. pylori could potentially lead to duodenal or gastric ulcer disease, asymptomatic chronic gastritis, chronic dyspepsia, or gastric malignancy, including both adenocarcinoma and B-cell lymphoma, a large number of different treatment regimens aimed at eradicating H. pylori has been evaluated and reported. Despite numerous H. pylori treatment studies the optimum regimen for its eradication remains unclear. A treatment regimen, which is effective, safe and inexpensive could be used widespread and reduce the risks of the long- term complications of infection. In this study we compared the efficacy, side effects and cost-effectiveness of 12 different therapy regimens for H. pylori eradication by using meta-analysis methodology. 486 patients (256 male, 230 female; mean age 40.8 years) with H. pylori associated duodenal ulcer (n = 140), gastritis (n = 254), gastroduodenitis (n = 92) were treated with 12 different therapy-regimens. Endoscopy was performed at baseline and 6 weeks after discontinuation of eradication therapy. H. pylori status was assessed by urease test and histology. The therapy with a H2-receptor antagonist is less effective than the triple therapies with omeprazole or lansoprazole. Bismuth-based triple therapies have a mean overall eradication rate of 68%, but are limited by frequent side effects causing poor drug compliance.